Abstract
The objective of this study was to explore whether hyperandrogenism induces epigenetic alterations of peroxisome proliferator-activated receptor gamma 1 (PPARG1), nuclear corepressor 1 (NCOR1), and histone deacetylase 3 (HDAC3) genes in granulosa cells (GCs) of polycystic ovary syndrome (PCOS) women and whether these alterations are involved in the ovarian dysfunction induced by hyperandrogenism. Thirty-two infertile PCOS women and 147 infertile women with tubal blockage were recruited. PCOS women were divided into the hyperandrogenism (HA) PCOS group (n = 13) and nonhyperandrogenism (N-HA) PCOS group (n = 19). Sixty female Sprague-Dawley rats were used for PCOS model establishment. In GCs of HA PCOS women, PPARG1 mRNA expression was lower, whereas NCOR1 and HDAC3 mRNA expression were higher than N-HA PCOS women and controls (P < 0.05). When all women were divided into successful and failed pregnancy subgroups according to the following clinical pregnancy outcome, we found lower PPARG1 mRNA levels and higher NCOR1 and HDAC3 mRNA levels in the failed subgroup of HA PCOS (P < 0.05). Two hypermethylated CpG sites in the PPARG1 promoter and five hypomethylated CpG sites in the NCOR1 promoter were observed only in HA PCOS women (P < 0.01 to P < 0.0005). The acetylation levels of histone H3 at lysine 9 and p21 mRNA expression were decreased in human GCs treated with dihydrotestosterone in vitro (P < 0.05). PCOS rat models also showed alterations of PPARG1, NCOR1, and HDAC3 mRNA expression and methylation changes of PPARG1 and NCOR1, consistent with the results from humans. Hyperandrogenism induces the epigenetic alterations of PPARG1, NCOR1, and HDAC3 in GCs, which are involved in the ovarian dysfunction of HA PCOS.
Similar content being viewed by others
References
Norman RJ, Dewailly D, Legro RS, Hickey TE (2007) Polycystic ovary syndrome. Lancet 370:685–697
Xita N, Tsatsoulis A (2006) Review: fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical, and genetic association studies. J Clin Endocrinol Metab 91:1660–1666
Dumesic DA, Abbott DH, Padmanabhan V (2007) Polycystic ovary syndrome and its developmental origins. Rev Endocr Metab Disord 8:127–141
Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R (2011) Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol 7:219–231
Froment P, Gizard F, Staels B, Dupont J, Monget P (2005) A role of PPARgamma in reproduction? Med Sci (Paris) 21:507–511
Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Rosenfield RL, Polonsky KS (1997) Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 82:2108–2116
Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, O'Keefe M, Ghazzi MN (2001) Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 86:1626–1632
Brettenthaler N, De Geyter C, Huber PR, Keller U (2004) Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 89:3835–3840
Sepilian V, Nagamani M (2005) Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. J Clin Endocrinol Metab 90:60–65
Gao Z, He Q, Peng B, Chiao PJ, Ye J (2006) Regulation of nuclear translocation of HDAC3 by IkappaBalpha is required for tumor necrosis factor inhibition of peroxisome proliferator-activated receptor gamma function. J Biol Chem 281:4540–4547
Guenther MG, Barak O, Lazar MA (2001) The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3. Mol Cell Biol 21:6091–6101
Jepsen K, Hermanson O, Onami TM, Gleiberman AS, Lunyak V, McEvilly RJ, Kurokawa R, Kumar V, Liu F, Seto E et al (2000) Combinatorial roles of the nuclear receptor corepressor in transcription and development. Cell 102:753–763
Bhaskara S, Chyla BJ, Amann JM, Knutson SK, Cortez D, Sun ZW, Hiebert SW (2008) Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Mol Cell 30:61–72
Alenghat T, Meyers K, Mullican SE, Leitner K, Adeniji-Adele A, Avila J, Bucan M, Ahima RS, Kaestner KH, Lazar MA (2008) Nuclear receptor corepressor and histone deacetylase 3 govern circadian metabolic physiology. Nature 456:997–1000
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41–47
Nikolettos N, Kupker W, Al-Hasani S, Demirel LC, Schopper B, Sturm R, Diedrich K (2000) ICSI outcome in patients of 40 years age and over: a retrospective analysis. Eur J Obstet Gynecol Reprod Biol 91:177–182
Qu F, Wang FF, Lu XE, Dong MY, Sheng JZ, Lv PP, Ding GL, Shi BW, Zhang D, Huang HF (2010) Altered aquaporin expression in women with polycystic ovary syndrome: hyperandrogenism in follicular fluid inhibits aquaporin-9 in granulosa cells through the phosphatidylinositol 3-kinase pathway. Hum Reprod 25:1441–1450
Seto-Young D, Avtanski D, Strizhevsky M, Parikh G, Patel P, Kaplun J, Holcomb K, Rosenwaks Z, Poretsky L (2007) Interactions among peroxisome proliferator activated receptor-gamma, insulin signaling pathways, and steroidogenic acute regulatory protein in human ovarian cells. J Clin Endocrinol Metab 92:2232–2239
Sayasith K, Bouchard N, Dore M, Sirois J (2008) Regulation of bovine tumor necrosis factor alpha induced protein 6 in ovarian follicles during the ovulatory process and promoter activation in granulosa cells. Endocrinology 149:6213–6225
Roberts R, Stark J, Iatropoulou A, Becker DL, Franks S, Hardy K (2004) Energy substrate metabolism of mouse cumulus-oocyte complexes: response to follicle-stimulating hormone is mediated by the phosphatidylinositol 3-kinase pathway and is associated with oocyte maturation. Bio Reprod 71:199–209
Tamura N, Kurabayashi T, Nagata H, Matsushita H, Yahata T, Tanaka K (2005) Effects of testosterone on cancellous bone, marrow adipocytes, and ovarian phenotype in a young female rat model of polycystic ovary syndrome. Fertil Steril 84(Suppl 2):1277–1284
Doi SA, Al-Zaid M, Towers PA, Scott CJ, Al-Shoumer KA (2006) Steroidogenic alterations and adrenal androgen excess in PCOS. Steroids 71:751–759
Olek A, Oswald J, Walter J (1996) A modified and improved method for bisulphite based cytosine methylation analysis. Nucleic Acids Res 24:5064–5066
Pigny P, Jonard S, Robert Y, Dewailly D (2006) Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab 91:941–945
Shalev E, Goldman S, Ben-Shlomo I (2001) The balance between MMP-9 and MMP-2 and their tissue inhibitor (TIMP)-1 in luteinized granulosa cells: comparison between women with PCOS and normal ovulatory women. Mol Hum Reprod 7:325–331
Karagianni P, Wong J (2007) HDAC3: taking the SMRT-N-CoRrect road to repression. Oncogene 26:5439–5449
Sun F, Yu J (2000) The effect of a special herbal tea on obesity and anovulation in androgen-sterilized rats. Proc Soc Exp Biol Med 223:295–301
Escobar-Morreale HF, Asuncion M, Calvo RM, Sancho J, San Millan JL (2001) Receiver operating characteristic analysis of the performance of basal serum hormone profiles for the diagnosis of polycystic ovary syndrome in epidemiological studies. Eur J Endocrinol 145:619–624
Koskinen P, Penttila TA, Anttila L, Erkkola R, Irjala K (1996) Optimal use of hormone determinations in the biochemical diagnosis of the polycystic ovary syndrome. Fertil Steril 65:517–522
Acknowledgements
We thank Dr. Run-Ju Zhang, Dr. Yan-Ting Wu, Dr. Xin-Mei Liu, Dr. Ting-Ting Wang, Dr. Xi-Jing Chen (Women’s Hospital, School of Medicine, Zhejiang University, Hangzhou, China), Ping-Ping Lv (School of Medicine, Zhejiang University, Hangzhou, China), and Dr. Jue Zhou (College of Food Science and Biotechnology, Zhejiang Gongshang University, Hangzhou, China) for their kind help with the present research.
Grants
This work was supported by the National Basic Research Program of China (2012CB944900), Key Projects in the National Science Technology Pillar Program in the Twelfth Five-Year Plan Period, China (no. 2012BAI32B00), China–Canada Joint Health Research Initiative—Grants Program (no. 30711120577), National Key Research Program of China (no. 2006CB944006), Zhejiang Provincial Natural Science Foundation of China (no. Z2110063), and Natural Science Foundation of Zhejiang Province, China (no. 2090387).
Disclosure statement
No commercial or other associations that might pose a conflict of interest in connection with the submitted material are to be disclosed.
Author information
Authors and Affiliations
Corresponding author
Additional information
Fan Qu and Fang-Fang Wang contributed equally to the study.
Precis
Hyperandrogenism induces methylation and acetylation alterations in ovaries, which are involved in the mechanism underlying ovarian dysfunction of polycystic ovary syndrome.
Rights and permissions
About this article
Cite this article
Qu, F., Wang, FF., Yin, R. et al. A molecular mechanism underlying ovarian dysfunction of polycystic ovary syndrome: hyperandrogenism induces epigenetic alterations in the granulosa cells. J Mol Med 90, 911–923 (2012). https://doi.org/10.1007/s00109-012-0881-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00109-012-0881-4